Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.

There is an urgent need to discover new, selective compounds to add to the limited arsenal of chemotherapeutics displaying selective toxicity for aggressive triple-negative breast cancer (TNBC) cells. The effect of two, recently developed metal-based half-sandwich complexes [Os(η6-pcym)(bphen)(dca)]PF6 (Os-dca) and [Ru(η6-pcym)(bphen)(dca)]PF6 (Ru-dca) [pcym = 1-methyl-4-(propan-2-yl)benzene (p-cymene); bphen = 4,7-diphenyl-1,10-phenanthroline (bathophenanthroline); dca = dichloroacetate] on triple-negative breast cancer cells MDA-MB-231 is reported. The complexes display selective toxicity in several tumor cells (at submicromolar concentrations), and a prominent effect is observed against highly progressive triple negative breast cancer MDA-MB-231 cells for Os-dca. The lower potency of Ru-dca in comparison with Os-dca is apparently connected with a relatively quick release of the dca ligand due to the hydrolysis of Ru-dca before this complex enters the cells. Remarkably, both Os-dca and Ru-dca reduce successfully metastasis-related properties of the triple-negative breast cancer cells such as migration, invasion, and re-adhesion. The anti-metastatic effects of Os-dca and Ru-dca are associated with their ability to suppress matrix metalloproteinase activity and/or production and reduce the expression of aquaporins. Further detailed mechanistic studies reveal that Os-dca reverses Warburg's effect and oncosis seems to be a prominent mode of cell death that predominates over apoptosis. As such, Os-dca can efficiently overcome the resistance of cancer cells to clinically-used apoptotic inducers cisplatin and carboplatin. The cytostatic and anti-metastatic properties of Os-dca in MDA-MB-231 provide a strong impetus for the development of new metal-based compounds to target hardly treatable human TNBC cells and displaying different modes of action compared to the antitumor metallodrugs in clinical use.

[1]  A. Casini,et al.  Aquaporins in cancer development: opportunities for bioinorganic chemistry to contribute novel chemical probes and therapeutic agents. , 2018, Metallomics : integrated biometal science.

[2]  Zhe-Sheng Chen,et al.  Oncosis-inducing cyclometalated iridium(iii) complexes , 2018, Chemical science.

[3]  W. Berger,et al.  Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. , 2018, Chemical Society reviews.

[4]  Z. Dvořák,et al.  Half-Sandwich Ru(II) and Os(II) Bathophenanthroline Complexes Containing a Releasable Dichloroacetato Ligand , 2018, Molecules.

[5]  J. Ellena,et al.  Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells , 2017, PloS one.

[6]  Jianliang Shen,et al.  A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer. , 2017, Nano letters.

[7]  V. Brabec,et al.  Novel Antitumor Platinum(II) Conjugates Containing the Nonsteroidal Anti-inflammatory Agent Diclofenac: Synthesis and Dual Mechanisms of Antiproliferative Effects. , 2017, Inorganic chemistry.

[8]  A. Ratanaphan,et al.  BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds. , 2016, Current cancer drug targets.

[9]  S. Kostrov,et al.  Cytoplasmic vacuolization in cell death and survival , 2016, Oncotarget.

[10]  V. Brabec,et al.  Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin. , 2016, Journal of inorganic biochemistry.

[11]  Guo-Qing Song,et al.  Kisspeptin 10 inhibits the Warburg effect in breast cancer through the Smad signaling pathway: both in vitro and in vivo. , 2016, American journal of translational research.

[12]  G. Murray,et al.  Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis , 2015, The Journal of pathology.

[13]  M. Papadopoulos,et al.  Key roles of aquaporins in tumor biology. , 2015, Biochimica et biophysica acta.

[14]  L. Liu,et al.  Effect of melatonin on oncosis of myocardial cells in the myocardial ischemia/reperfusion injury rat and the role of the mitochondrial permeability transition pore. , 2015, Genetics and molecular research : GMR.

[15]  V. Brabec,et al.  Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity. , 2015, Dalton transactions.

[16]  M. Hanif,et al.  Development of anticancer agents: wizardry with osmium. , 2014, Drug discovery today.

[17]  M. Hemann,et al.  A Breast Cancer Stem Cell-Selective, Mammospheres-Potent Osmium(VI) Nitrido Complex , 2014, Journal of the American Chemical Society.

[18]  P. Sadler,et al.  A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex. , 2014, Metallomics : integrated biometal science.

[19]  T. Sørlie,et al.  Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy , 2014, The British journal of surgery.

[20]  A. Vessières,et al.  Cytotoxic Triosmium Carbonyl Clusters: A Structure–Activity Relationship Study , 2014, ChemMedChem.

[21]  S. Dhar,et al.  Mito-DCA: A Mitochondria Targeted Molecular Scaffold for Efficacious Delivery of Metabolic Modulator Dichloroacetate , 2014, ACS chemical biology.

[22]  A. Ratanaphan,et al.  Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine , 2014, BMC Cancer.

[23]  P. Sadler,et al.  Mirror-Image Organometallic Osmium Arene Iminopyridine Halido Complexes Exhibit Similar Potent Anticancer Activity , 2013, Chemistry.

[24]  J. Whitehead,et al.  Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib , 2013, British Journal of Cancer.

[25]  Robert E. Brown,et al.  A model for cardiomyocyte cell death: insights into mechanisms of oncosis. , 2013, Experimental and molecular pathology.

[26]  H. Jeon,et al.  Aquaporin-5: A Marker Protein for Proliferation and Migration of Human Breast Cancer Cells , 2011, PloS one.

[27]  P. Sadler,et al.  Differences in the cellular response and signaling pathways between cisplatin and monodentate organometallic Ru(II) antitumor complexes containing a terphenyl ligand. , 2011, Molecular pharmaceutics.

[28]  Q. Lu,et al.  Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. , 2011, International journal of oncology.

[29]  D. Newton,et al.  Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC , 2010, International journal of cancer.

[30]  P. Sadler,et al.  Organometallic osmium arene complexes with potent cancer cell cytotoxicity. , 2010, Journal of medicinal chemistry.

[31]  C. Santiskulvong,et al.  Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix‐metalloproteinase expression , 2010, Cytoskeleton.

[32]  R. Shi,et al.  Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. , 2010, Breast.

[33]  J. Mackey,et al.  Metabolic Modulation of Glioblastoma with Dichloroacetate , 2010, Science Translational Medicine.

[34]  K. Syrigos,et al.  Cell Adhesion Molecules: Role and Clinical Significance in Cancer , 2009, Cancer investigation.

[35]  L. Carey,et al.  Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. , 2009, Clinical breast cancer.

[36]  W. Leong,et al.  Osmium carbonyl clusters containing labile ligands hyperstabilize microtubules. , 2009, Chemical research in toxicology.

[37]  W. Leong,et al.  Induction of apoptosis by hexaosmium carbonyl clusters , 2009 .

[38]  M. Andreeff,et al.  Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. , 2009, Cancer research.

[39]  J. Mackey,et al.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer , 2008, British Journal of Cancer.

[40]  Guillermo Repetto,et al.  Neutral red uptake assay for the estimation of cell viability/cytotoxicity , 2008, Nature Protocols.

[41]  V. Brabec,et al.  Cytotoxicity, mutagenicity, cellular uptake, DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamine. , 2008, Journal of inorganic biochemistry.

[42]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Condeelis,et al.  Regulation of the actin cytoskeleton in cancer cell migration and invasion. , 2007, Biochimica et biophysica acta.

[44]  E. Hoffmann,et al.  Cell shrinkage as a signal to apoptosis in NIH 3T3 fibroblasts , 2005, The Journal of physiology.

[45]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[46]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[47]  A. Bergamo,et al.  Ruthenium antimetastatic agents. , 2004, Current topics in medicinal chemistry.

[48]  J. Jakubikova,et al.  An investigation of the genotoxic effects of N-nitrosomorpholine in mammalian cells. , 2004, Chemico-biological interactions.

[49]  L. Kreja,et al.  Evaluation of the genotoxic potential of some microbial volatile organic compounds (MVOC) with the comet assay, the micronucleus assay and the HPRT gene mutation assay. , 2002, Mutation research.

[50]  G. Freeman,et al.  Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Gu,et al.  A cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Schellens,et al.  Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. , 2012, Journal of inorganic biochemistry.

[53]  Anna F. A. Peacock,et al.  In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. , 2010, Journal of inorganic biochemistry.

[54]  S. Lipkowitz,et al.  Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. , 2010, Breast disease.

[55]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[56]  Henriqueta Louro,et al.  Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells , 2005, Environmental and molecular mutagenesis.